Humacyte (HUMA) News Today $4.41 -0.07 (-1.56%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Humacyte FY2024 EPS Estimate Increased by Cantor FitzgeraldJanuary 19 at 2:13 AM | americanbankingnews.comCantor Fitzgerald Increases Earnings Estimates for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Humacyte in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1January 18 at 1:13 AM | marketbeat.comHumacyte (NASDAQ:HUMA) Stock Price Up 10% - Time to Buy?Humacyte (NASDAQ:HUMA) Trading 10% Higher - Should You Buy?January 17 at 6:52 PM | marketbeat.comHUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 17 at 10:47 AM | globenewswire.comFaruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAJanuary 17 at 9:44 AM | globenewswire.comCantor Fitzgerald Forecasts Stronger Earnings for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($1.40) per sJanuary 17 at 6:40 AM | marketbeat.comLevi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMAJanuary 17 at 5:45 AM | prnewswire.comHumacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMAJanuary 17 at 5:14 AM | prnewswire.comHumacyte (NASDAQ:HUMA) Stock Price Down 6.4% - What's Next?Humacyte (NASDAQ:HUMA) Stock Price Down 6.4% - What's Next?January 16, 2025 | marketbeat.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 16, 2025 | globenewswire.comShareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMAJanuary 16, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest UpdateHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 29,620,000 shares, a growth of 34.9% from the December 15th total of 21,960,000 shares. Based on an average daily volume of 4,700,000 shares, the days-to-cover ratio is currently 6.3 days. Currently, 28.4% of the company's shares are short sold.January 16, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 16, 2025 | prnewswire.comHUMA Lawsuit Alert! Class Action Against Humacyte, Inc.January 16, 2025 | tipranks.comThe Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 16, 2025 | prnewswire.comHumacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Target Price from AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and oJanuary 16, 2025 | marketbeat.comThe Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAJanuary 15, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of HumacyteJanuary 15, 2025 | prnewswire.comD. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)January 15, 2025 | americanbankingnews.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming Deadlines - HUMAJanuary 14, 2025 | prnewswire.comHUMA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 14, 2025 | globenewswire.comHumacyte (NASDAQ:HUMA) Trading Down 6.4% - Should You Sell?Humacyte (NASDAQ:HUMA) Shares Down 6.4% - Here's WhyJanuary 14, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 14, 2025 | prnewswire.comContact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA)January 14, 2025 | prnewswire.comHUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 13, 2025 | investing.comHumacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular TraumaJanuary 13, 2025 | markets.businessinsider.comHumacyte provides update on commerical launch, pricing of SymvessJanuary 13, 2025 | markets.businessinsider.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitJanuary 13, 2025 | prnewswire.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 13, 2025 | prnewswire.comHumacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMAJanuary 13, 2025 | globenewswire.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 13, 2025 | prnewswire.comHumacyte (NASDAQ:HUMA) Receives Buy Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a report on Monday.January 13, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from BrokeragesJanuary 13, 2025 | americanbankingnews.comHumacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Buy" from BrokeragesHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy ratingJanuary 13, 2025 | marketbeat.comClass Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law FirmJanuary 13, 2025 | prnewswire.comHumacyte, Inc. (NASDAQ:HUMA) Position Increased by Barclays PLCBarclays PLC boosted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 177.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 236,742 shares of the company's stock after acquiring an additional 151,458 shareJanuary 13, 2025 | marketbeat.comHUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 12, 2025 | investing.comHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. ...January 12, 2025 | gurufocus.comHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 12, 2025 | globenewswire.comHUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. ...January 11, 2025 | gurufocus.comHUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 11, 2025 | globenewswire.comHumacyte, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. January 17, 2025 Deadline to file Lead Plaintiff MotionJanuary 10, 2025 | globenewswire.comHUMA INVESTOR ALERT: Kirby McInerney LLP Reminds Humacyte, Inc. ...January 10, 2025 | gurufocus.comHUMA INVESTOR ALERT: Kirby McInerney LLP Reminds Humacyte, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitJanuary 10, 2025 | globenewswire.comHumacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAJanuary 10, 2025 | prnewswire.comHUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 9, 2025 | globenewswire.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMAJanuary 9, 2025 | prnewswire.comHumacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A BeginningJanuary 9, 2025 | seekingalpha.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitJanuary 9, 2025 | prnewswire.comShareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMAJanuary 8, 2025 | globenewswire.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.220.44▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼319▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGON News Today PTGX News Today NAMS News Today JANX News Today VERA News Today IBRX News Today CNTA News Today MESO News Today BEAM News Today IDYA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts